Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

(2009) K. R. Carson et al.   BLOOD

Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab

(2008) R. Stasi et al.   BLOOD

Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study

(2008) B. Godeau et al.   BLOOD

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group

(2008) F. Rodeghiero et al.   BLOOD

Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results

(2008) Marta Medeot et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura

(2008) F. Zaja et al.   HAEMATOLOGICA

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial

(2008) David J Kuter et al.   LANCET

One year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab

(2008) Brigitta U. Mueller et al.   PEDIATRIC BLOOD & CANCER